Ella Borgman, Camille Le Gall, Hidde Ploegh, Novalia Pishesha
{"title":"Fc-engineering for improved cancer immunotherapy.","authors":"Ella Borgman, Camille Le Gall, Hidde Ploegh, Novalia Pishesha","doi":"10.1042/BST20250554","DOIUrl":null,"url":null,"abstract":"<p><p>Monoclonal antibodies have revolutionized cancer therapy, with approved therapeutics belonging predominantly to the immunoglobulin G (IgG) class. These IgGs mediate antitumor effects predominantly through engagement of Fcγ receptors on immune cells. This engagement results in therapy-activating Fc effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Limitations nonetheless include suboptimal effector engagement and adverse immunological side effects. These drawbacks have driven the search for and optimization of Fc-engineering strategies, including Fc mutations, glycan modification, and choice of Ig isotype, to enhance therapeutic efficacy and tailor immune interactions.</p>","PeriodicalId":8841,"journal":{"name":"Biochemical Society transactions","volume":"54 8","pages":"1117-1130"},"PeriodicalIF":4.4000,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13500781/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical Society transactions","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1042/BST20250554","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Monoclonal antibodies have revolutionized cancer therapy, with approved therapeutics belonging predominantly to the immunoglobulin G (IgG) class. These IgGs mediate antitumor effects predominantly through engagement of Fcγ receptors on immune cells. This engagement results in therapy-activating Fc effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Limitations nonetheless include suboptimal effector engagement and adverse immunological side effects. These drawbacks have driven the search for and optimization of Fc-engineering strategies, including Fc mutations, glycan modification, and choice of Ig isotype, to enhance therapeutic efficacy and tailor immune interactions.
期刊介绍：
Biochemical Society Transactions is the reviews journal of the Biochemical Society. Publishing concise reviews written by experts in the field, providing a timely snapshot of the latest developments across all areas of the molecular and cellular biosciences.
Elevating our authors’ ideas and expertise, each review includes a perspectives section where authors offer comment on the latest advances, a glimpse of future challenges and highlighting the importance of associated research areas in far broader contexts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
